Theranostics 2021; 11(20):9752-9771. doi:10.7150/thno.63806 This issue Cite

Research Paper

USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2

Arun Pandian Chandrasekaran1, Kamini Kaushal1, Chang-Hwan Park1,2, Kye-Seong Kim1,2✉, Suresh Ramakrishna1,2✉

1. Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, South Korea.
2. College of Medicine, Hanyang University, Seoul, South Korea.

Citation:
Chandrasekaran AP, Kaushal K, Park CH, Kim KS, Ramakrishna S. USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2. Theranostics 2021; 11(20):9752-9771. doi:10.7150/thno.63806. https://www.thno.org/v11p9752.htm
Other styles

File import instruction

Abstract

Graphic abstract

Background: The most commonly preferred chemotherapeutic agents to treat cancers are small-molecule drugs. However, the differential sensitivity of various cancer cells to small molecules and untargeted delivery narrow the range of potential therapeutic applications. The mechanisms responsible for drug resistance in a variety of cancer cells are also largely unknown. Several deubiquitinating enzymes (DUBs) are the main determinants of drug resistance in cancer cells.

Methods: We used CRISPR-Cas9 to perform genome-scale knockout of the entire set of genes encoding ubiquitin-specific proteases (USPs) and systematically screened for DUBs resistant to the clinically evaluated anticancer compound YM155. A series of in vitro and in vivo experiments were conducted to reveal the relationship between USP32 and SLC35F2 on YM155-mediated DNA damage in cancer cells.

Results: CRISPR-based dual-screening method identified USP32 as a novel DUB that governs resistance for uptake of YM155 by destabilizing protein levels of SLC35F2, a solute-carrier protein essential for the uptake of YM155. The expression of USP32 and SLC35F2 was negatively correlated across a panel of tested cancer cell lines. YM155-resistant cancer cells in particular exhibited elevated expression of USP32 and low expression of SLC35F2.

Conclusion: Collectively, our DUB-screening strategy revealed a resistance mechanism governed by USP32 associated with YM155 resistance in breast cancers, one that presents an attractive molecular target for anti-cancer therapies. Targeted genome knockout verified that USP32 is the main determinant of SLC35F2 protein stability in vitro and in vivo, suggesting a novel way to treat tumors resistant to small-molecule drugs.

Keywords: DNA damage, dose response, human tumor tissues, cell apoptosis, drug transport-cargo


Citation styles

APA
Chandrasekaran, A.P., Kaushal, K., Park, C.H., Kim, K.S., Ramakrishna, S. (2021). USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2. Theranostics, 11(20), 9752-9771. https://doi.org/10.7150/thno.63806.

ACS
Chandrasekaran, A.P.; Kaushal, K.; Park, C.H.; Kim, K.S.; Ramakrishna, S. USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2. Theranostics 2021, 11 (20), 9752-9771. DOI: 10.7150/thno.63806.

NLM
Chandrasekaran AP, Kaushal K, Park CH, Kim KS, Ramakrishna S. USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2. Theranostics 2021; 11(20):9752-9771. doi:10.7150/thno.63806. https://www.thno.org/v11p9752.htm

CSE
Chandrasekaran AP, Kaushal K, Park CH, Kim KS, Ramakrishna S. 2021. USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2. Theranostics. 11(20):9752-9771.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.